Check for updates

# Interleukin-18 Regulation of Interferon γ Production and Cell Proliferation as Shown in Interleukin-1β–Converting Enzyme (Caspase-1)-Deficient Mice

By Giamila Fantuzzi, Adrian J. Puren, Matthew W. Harding, David J. Livingston, and Charles A. Dinarello

Interleukin-18 (IL-18) is a costimulatory factor for interferon $\gamma$  (IFN $\gamma$ ) production. Processing of pro-IL-18 by IL-1 $\beta$ -converting enzyme (ICE) leads to the release of bioactive IL-18. Compared with wild-type (WT) mice, splenocytes from ICE-deficient mice produced low IFN $\gamma$  after lipopolysaccharide (LPS) or zymosan (50% and 80% reduction). In contrast, IFN $\gamma$  production was unimpaired in ICE-deficient mice using Concanavalin A (Con A). Comparable results were obtained when endogenous IL-18 was blocked with a neutralizing antibody. LPS-induced IFN $\gamma$  was also reduced by an ICE inhibitor. Exogenous IL-18 augmented zymosan-induced IFN $\gamma$  production in WT mice. In ICE-deficient cells, IFN $\gamma$  production was only partially restored by IL-18. The reduced levels of IFN $\gamma$  in ICE-deficient mice were not due to a lack of IL-12, because zymosan induced IL-12 equally in WT and in ICE-

**T**NTERFERON  $\gamma$  (IFN $\gamma$ )-inducing factor (IGIF or interleukin-18 [IL-18]) is a recently characterized cytokine that acts as a costimulatory factor for the production of IFN $\gamma$ . IL-18 was initially purified and subsequently cloned from the liver of mice conditioned with *Propionibacterium acnes* and challenged with lipopolysaccharide (LPS);<sup>1,2</sup> cloning of the human molecule has also been recently described.<sup>3</sup> A critical role for IL-18 in LPS-induced toxicity has been shown. Anti–IL-18 antibodies protect *P acnes*-conditioned mice from liver injury after LPS.<sup>2</sup> In addition, a role for IL-18 in the pathogenesis of insulindependent diabetes mellitus has recently been proposed.<sup>4</sup>

Similar to another IFN $\gamma$ -inducing factor, IL-12, IL-18 is produced by monocytes/macrophages, but not by B or T cells.<sup>3</sup> However, IL-18 induction of IFN $\gamma$  is independent of IL-12 production. In fact, anti–IL-12 antibodies do not inhibit the increase in anti–CD3-stimulated IFN $\gamma$  production induced by IL-18.<sup>2</sup> In addition to acting as a costimulus for IFN $\gamma$  production, IL-18 enhances the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-2,<sup>5</sup> potentiates anti–CD3-induced T-cell proliferation,<sup>5</sup> and increases Fasmediated killing of natural killer (NK) cells by augmenting the expression of Fas ligand.<sup>6</sup> However, unlike IL-12, IL-18 by itself, in the absence of another stimulus, is not a strong inducer of IFN $\gamma$ .<sup>3</sup>

IL-18 is structurally related to IL-1 $\beta$ , with both cytokines having a unique, all- $\beta$ -pleated structure.<sup>7</sup> Also, similar to

© 1998 by The American Society of Hematology. 0006-4971/98/9106-0038\$3.00/0

deficient mice. IFN $\gamma$  is an important regulator of cell proliferation. In accordance, splenocytes from ICE-deficient mice proliferated more when stimulated with LPS, but not with Con A. Furthermore, in ovalbumin-sensitized ICE-deficient mice, proliferation of lymph node cells in response to the specific antigen was not altered. Exogenous IFN $\gamma$  inhibited, whereas blockade of endogenous IFN $\gamma$  or IL-18 increased, LPS induced splenocyte proliferation both in WT and in ICE-deficient mice. Our results show that IL-18 is an IL-12-independent regulator of IFN $\gamma$  production and of cell proliferation induced by microbial stimuli. However, ICE-dependent processing of IL-18 is not needed for response to mitogens or antigens.

© 1998 by The American Society of Hematology.

IL-1 $\beta$ , IL-18 is synthesized as a precursor lacking a typical signal peptide.<sup>3</sup> Pro–IL-18, as pro–IL-1 $\beta$ , is devoid of biological activity and precursor amino acids must be cleaved to produce an active molecule.<sup>3</sup> IL-1 $\beta$ –converting enzyme (ICE; caspase-1), which cleaves pro–IL-1 $\beta$ , also cleaves pro–IL-18 at aspartic acid in the P1 position, producing a mature, bioactive peptide that is readily released from the cell.<sup>8,9</sup> When ICE-deficient mice are injected with LPS, with or without a preconditioning with *P acnes*, only low levels of IFN $\gamma$  are detectable in the circulation compared with wild-type (WT) mice.<sup>8,9</sup> The injection of IL-18 restores the LPS-induced IFN $\gamma$  levels in ICE-deficient mice,<sup>8</sup> supporting the concept that ICE is actually involved in the production of active IL-18.

To date, the role of endogenous IL-18 in the induction of IFN $\gamma$  after stimuli other than LPS remains unknown. To help elucidate the role of IL-18 in the regulation of IFN $\gamma$  production in response to various stimuli, we studied the in vitro production of IFN $\gamma$  in splenocytes from ICE-deficient mice using two inflammatory stimuli, LPS and zymosan, and compared it with the response to an immune stimulus, the mitogen Concanavalin A (Con A). In addition, because IFN $\gamma$  is an important factor regulating cell proliferation,<sup>10,11</sup> we investigated the response of splenocytes obtained from WT and ICE-deficient mice to mitogenic concentrations of LPS and Con A, as well as to specific antigen.

### MATERIALS AND METHODS

*Materials.* LPS (a phenol-extracted preparation from *Escherichia coli* 055:B5), zymosan, Con A, ovalbumin, and phenazine methosulfate (PMS) were purchased from Sigma Chemical Co (St Louis, MO); RPMI was from Cellgro (Waukesha, WI); fetal bovine serum (FBS) was from GIBCO (Pascagoula, MS); MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt] was from Promega (Madison, WI); the reversible ICE inhibitor Ac-Tyr-Val-Ala-Asp-CHO was from Alexis (San Diego, CA); rat recombinant IFN $\gamma$  was from Genentech (South San Francisco, CA); human recombinant IL-1Ra was a kind gift from Dr Daniel Tracey (Upjohn, Kalamazoo, MI); murine recombinant IL-18 was a kind gift from Dr Y. Stabinsky (Peprotech, Inc, Princeton, NJ). The anti–IL-18 antiserum was obtained from a New Zealand rabbit immunized by intradermal injection of murine recombinant IL-18 (Peprotech) in the presence of Hunter's Titermax adjuvant. After several booster injec-

From the Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO; and the Vertex Pharmaceuticals, Inc, Cambridge, MA.

Submitted July 25, 1997; accepted October 30, 1997.

Supported by National Institutes of Health Grant No. AI-15614.

Address reprint requests to Charles A. Dinarello, MD, Division of Infectious Diseases, University of Colorado Health Sciences Center, 4200 E Ninth Ave, B168, Denver, CO 80262.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

tions, blood was collected and serum obtained. The anti-IFNγ monoclonal antibody (XMG1.2) was from Endogen Inc (Woburn, MA).

Animals. The generation and genetic background of ICE- and of IL-1 $\beta$ -deficient mice has been previously described.<sup>12,13</sup> Six- to eightweek-old, sex-matched mice were used. The WT mice used were of the same genetic background, sex, and age as that of the knock out mice, although they were not littermates.

Isolation and culture of spleen and lymph node cells. Spleens were aseptically removed and cell suspensions were prepared according to standard procedures.<sup>14</sup> Cells were washed twice and resuspended in RPMI supplemented with 10% FBS. For cytokine measurement, spleen cells were cultured at  $5 \times 10^6$ /mL in 24-well, flat-bottom culture plates in the presence or absence of various concentrations of LPS, zymosan, or Con A. When zymosan was the stimulus, 1% human serum was added to the culture to opsonize zymosan particles. Cultures were incubated at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. At the end of the incubation period, cultures were frozen at  $-70^\circ$ C and subjected to 3 freeze-thaw cycles to obtain total cytokine levels. Before assaying, samples were centrifuged for 10 minutes at 10,000g to remove debris.

For proliferation assays, spleen cells were cultured in triplicate wells at  $2.5 \times 10^{6}$ /mL in 96-well, flat-bottom microtiter plates with increasing concentrations of either LPS (4, 20, and 100 µg/mL) or Con A (1, 3, and 10 µg/mL). Proliferation was measured using the MTS/PMS method, as previously described.<sup>15</sup>

For the evaluation of the proliferative response after ovalbumin, mice were injected at the base of the tail with a suspension of 50 mg of OVA in 100  $\mu$ L complete Freund adjuvant (CFA). Fourteen days later, the draining abdominal periaortic lymph nodes were removed, cell suspensions were prepared, and cells were cultured at 2.5 × 10<sup>6</sup>/mL in 96-well, flat-bottom microtiter plates with increasing concentration of ovalbumin (50, 170, and 500 µg/mL).

Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from spleen cells as previously described.<sup>16</sup> One microgram of RNA was reverse transcribed using random hexamer primers (Perkin Elmer, Norwalk, CT) in a thermocycler (42°C for 30 minutes and 99°C for 5 minutes) and the cDNA amplification was performed as previously decribed for 30 cycles for cytokine expression and 24 cycles for GAPDH.<sup>16</sup> Oligonucleotide primers were as follows: p40 forward, 5'-CGTGCTATGGCTGGTGCAAAG-3'; p40 reverse, 5'-GAACACATGCCCACTTGCTG-3'; p35 forward, 5'-ACCAGCA-CATTGAAGACCTG-3'; p35 reverse, 5'-GACTGCATCAGCTCATCGAT-3'; GAPDH forward, 5'-TGAAGGTCGGAGTCAACGGATTTGGT-3'; and GAPDH reverse, 5'-CATGTGGGCCATGAGGTCCACCAC-3'. The annealing temperature was 60°C. Products of PCR amplifications were separated in a 2.0% agarose gel (Sigma) containing ethidium bromide (0.5 µg/mL) and 0.5× Tris-Borate-EDTA buffer (Fisher Scientific, Pittsburgh, PA). PCR amplification products were illuminated with UV light and a negative image photograph taken (Polaroid type 55 film; Polaroid, Cambridge, MA). The photographs were scanned on a densitometer using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Data are presented as the ratio of cytokine densitometric units to the GAPDH units for each condition.

Cytokine measurement. IFN $\gamma$  was measured with an enzymelinked immunosorbent assay (ELISA) kit, kindly provided by Endogen, Inc. Total and p70 IL-12 were measured with ELISA kits kindly provided by Genzyme Corp (Cambridge, MA).

#### RESULTS

Inhibition of ICE activity reduces LPS-induced IFN $\gamma$  production. Splenocytes from WT mice were cultured for 24 hours with LPS (1µg/mL) in the presence or absence of an ICE inhibitor (20 µmol/L) or of IL-1Ra (10 µg/mL). As shown in Fig 1, the ICE inhibitor reduced IFN $\gamma$  production by 70% (P < .01), whereas IL-1Ra had no significant effect.



Fig 1. An ICE inhibitor, but not IL-1Ra, reduces LPS-induced IFN<sub>Y</sub> production. Splenocytes from WT mice were incubated with LPS alone (1 µg/mL) or with LPS the presence of either IL-1Ra (10 µg/mL) or of an ICE inhibitor (20 µmol/L). IFN<sub>Y</sub> levels were measured 24 hours later. Data are the mean ± SEM of 6 mice per group. \*\**P* < .01 versus LPS alone by ANOVA for repeated measures.

Reduced production of IFNy in ICE-deficient mice. Splenocytes obtained from WT or ICE-deficient mice were cultured in vitro for 24 hours in the presence of various concentrations of LPS, zymosan, or Con A. Significantly lower levels of IFNy were produced in cultures from ICE-deficient splenocytes stimulated with either LPS (Fig 2A) or zymosan (Fig 2B). However, when Con A was used as a stimulus, the production of IFN $\gamma$  in ICE-deficient mice did not differ from that observed in WT mice (Fig 2C). These differences between WT and ICEdeficient mice were observed at each time point over 72 hours of culture. As shown in Fig 3A, significantly lower levels of IFNy were found in cultures of ICE-deficient splenocytes stimulated with LPS for 24, 48, or 72 hours. Markedly reduced levels of IFNy were also measured from ICE-deficient splenocytes stimulated with zymosan for 12, 24, 48, or 72 hours (Fig 3B). In contrast, no differences between WT and ICE-deficient mice were observed at any time point when the cells were stimulated with Con A (Fig 3C).

Because the most striking differences between WT and ICE-deficient mice for IFN $\gamma$  production were observed after zymosan, this stimulus was chosen for further investigation.

Effect of blockade of endogenous IL-18 on IFN $\gamma$  production. Splenocytes from WT mice were incubated for 24 or 72 hours with LPS (1  $\mu$ g/mL), zymosan (10  $\mu$ g/mL), or Con A (1  $\mu$ g/mL) in the presence of different dilutions of anti-IL-18 antiserum. As shown in Table 1, blockade of endogenous IL-18 significantly reduced LPS- and zymosan-induced IFNy at both 24 and 72 hours, but did not significantly alter IFNy production when Con A was the stimulus. At a 1:100 dilution of anti-IL-18 antiserum, 24-hour LPS-induced IFNy was inhibited by 83%, whereas zymosan-induced IFNy was inhibited by 66% compared with controls. The effect of the anti-IL-18 antiserum was even more evident in the 72-hour culture. At this time point, a 1:100 dilution of antiserum reduced LPS-induced IFNy production by 90% and zymosan-induced IFNy levels by 75%. Addition of normal rabbit serum did not significanly alter IFN $\gamma$ production after any of the three stimuli used, thus ruling out a possible nonspecific effect of rabbit serum on IFNy levels (data not



Fig 2. IFN<sub>Y</sub> production in splenocytes from WT and ICE-deficient mice. Splenocytes from WT ( $\bullet$ ) or ICE-deficient ( $\bigcirc$ ) mice were incubated with the indicated concentration of LPS (A), zymosan (B), or Con A (C) for 24 hours and levels of IFN<sub>Y</sub> measured. Data are the mean ± SEM of 9 mice per group. \**P* < .05; \*\**P* < .01 versus WT by factorial ANOVA.

Con A (µg/ml)

Table 1. Effect of IL-18 Blockade on IFNγ Production After
Stimulation With LPS, Zymosan, or Con A

	No Antiserum	Anti–IL-18 1:400	Anti-IL-18 1:200	Anti-IL-18 1:100
24 hours				
LPS	$12.99\pm1.40$	$6.52 \pm 3.55^{*}$	$3.84 \pm 2.361$	$2.18 \pm 1.221$
Zymosan	$10.89\pm1.71$	$9.82\pm2.74$	$5.11 \pm 1.86^{*}$	$3.74 \pm 1.53^{*}$
Con A	$48.30\pm6.03$	$45.85\pm7.23$	$47.26 \pm 7.57$	$42.65\pm6.81$
72 hours				
LPS	$22.60\pm7.50$	$5.00 \pm 1.95 \dagger$	$3.40\pm1.85\dagger$	$2.35 \pm 1.45 \dagger$
Zymosan	17.58 ± 2.84	$5.27 \pm 0.61 \dagger$	6.50 ± 3.17†	4.34 ± 1.60†

Splenocytes from WT mice were incubated with LPS (1 µg/mL), zymosan (10 µg/mL), or Con A (1 µg/mL) for 24 or 72 hours in the presence or absence of rabbit antimurine IL-18 antiserum at the indicated dilutions. Addition to the cultures of normal rabbit serum at the same concentrations did not significantly alter IFN<sub>Y</sub> production (data not shown). IFN<sub>Y</sub> levels were measured by ELISA. Data are the mean  $\pm$  SEM of 3 mice per group. \**P* < .05.

 $\dagger P < .01$  versus respective "No Antiserum" by ANOVA for repeated measures.

shown). These data confirm the results obtained in ICEdeficient mice and show that endogenous IL-18 actually plays a critical role in the induction of IFN $\gamma$  after LPS or zymosan.

Induction of IL-12 in ICE-deficient mice. Because IL-12 is a potent inducer of IFN $\gamma$ ,<sup>17</sup> we investigated whether the reduced levels of IFNy in ICE-deficient mice are due to a deficient production of this cytokine. However, despite an 80% reduced IFNy production in zymosan-stimulated ICE-deficient spleen cells, steady-state mRNA expression for both the p40 and the p35 subunits of IL-12 was induced equally in WT and in ICE-deficient mice (Fig 4). At the protein level, no differences were observed between WT and ICE-deficient mice for production of the active p70 heterodimer 24 hours after stimulation with zymosan (9.68  $\pm$  1.39 and 10.22  $\pm$  1.70 pg/mL in WT and ICE-deficient mice, respectively). However, levels of zymosanstimulated total IL-12 (as assessed by an ELISA kit that measures p40 monomer, p40 homodimer, and p70 heterodimer) were higher in ICE-deficient mice compared with WT (496.72  $\pm$  42.58 and 879.09  $\pm$  88.46 pg/mL in WT and ICE-deficient mice, respectively; P < .01 by Student's *t*-test).

Effect of IL-18 on IFN $\gamma$  production. To assess whether the reduced levels of IFNy observed in ICE-deficient mice could be normalized by addition of exogenous IL-18, splenocytes were stimulated with zymosan in the presence of increasing concentrations of IL-18. As shown in Fig 5, IL-18 increased zymosaninduced IFNy production both in WT and in ICE-deficient mice. At 1 ng/mL, IL-18 added to cultures of ICE-deficient splenocytes restored IFNy production to levels no longer significantly different from those observed in WT cells stimulated with zymosan alone. However, this concentration of IL-18 markedly increased IFNy production in WT mice. At 1 ng/mL IL-18, a ninefold and a threefold increase in IFNy production was observed in ICE-deficient and in WT mice, respectively. The difference in IFNy production between WT and ICE-deficient mice could not be narrowed even when higher concentrations of IL-18 were used. At 100 ng/mL of IL-18, splenocytes from ICE-deficient mice produced 29.05  $\pm$  10.06 ng/mL of IFN $\gamma$ , whereas cells from WT mice produced 59.86  $\pm$  9.85 ng/mL of



Fig 3. Time course of IFN $\gamma$  production in splenocytes from WT and ICE-deficient mice. Splenocytes from WT ( $\bullet$ ) or ICE-deficient ( $\bigcirc$ ) mice were incubated for the indicated times with 1 µg/mL of LPS (A), 10 µg/mL of zymosan (B), or 1 µg/mL of ConA (C) and levels of IFN $\gamma$  were measured. Data are the mean ± SEM of 6 mice per group. \**P* < .05 versus WT by factorial ANOVA.



Fig 4. Zymosan-induced IL-12 mRNA in WT and ICE-deficient mice. Splenocytes from WT and ICE-deficient mice were incubated for 4 hours with RPMI or 10  $\mu$ g/mL of zymosan. RT-PCR was performed for the p40 and p35 subunits of IL-12. Minor nonspecific amplicons were noted when p40 was amplified. GAPDH was used as an internal control. Amplification products for p40, p35, and GAPDH for 3 WT and 3 KO mice are shown in (A) (C, RPMI; Z, Zymosan). (B) shows mRNA ratios (mean ± SEM, n = 3).

IFN $\gamma$ . Although the augmentation in IFN $\gamma$  production using 100 ng/mL of IL-18 in ICE-deficient splenocytes represents a 56-fold increase over zymosan alone, the total IFN $\gamma$  production was still 50% lower than that observed in WT splenocytes.

These findings may reflect the lack of an additional factor involved in IFN $\gamma$  production in ICE-deficient mice. However, zymosan-induced IFN $\gamma$  production was not suppressed in splenocytes obtained from IL-1 $\beta$ -deficient mice (4.71 ± 2.51 ng/mL and 5.93 ± 1.93 ng/mL in WT and IL-1 $\beta$ -deficient mice, respectively, with 1 µg/mL of zymosan). Therefore, a lack of IL-1 $\beta$  release in splenocytes from ICE-deficient mice does not account for the reduced IFN $\gamma$  production after zymosan stimulation.

*Mitogenic responses in ICE-deficient mice.* Splenocytes from WT or ICE-deficient mice were incubated with increasing concentrations of LPS and proliferation assessed after 72 hours. We consistently observed a greater proliferation rate in cells obtained from ICE-deficient compared with WT mice at each of the LPS concentrations tested (Fig 6A). The increase in spleen cell proliferation in ICE-deficient mice ranged from 10% to 60%, depending on the experiment and the dose of LPS used.



Fig 5. Effect of IL-18 on IFN $\gamma$  production. Splenocytes from WT ( $\boxtimes$ ) or ICE-deficient ( $\square$ ) mice were incubated for 24 hours with 10  $\mu$ g/mL of zymosan in the presence of increasing concentrations of IL-18 and levels of IFN $\gamma$  were measured. Data are the mean ± SEM of 5 mice per group. The unpaired Student's *t*-test was used for comparison between WT and ICE-deficient mice, whereas for comparisons within a group, ANOVA for repeated measures was used.

On the other hand, when Con A was used as a mitogen, no significant difference was observed between WT and ICE-deficient mice (Fig 6B). Comparable results were obtained when LPS- or Con A-induced proliferation was measured at either 48 or 96 hours (data not shown).

In addition, no significant differences between WT and ICE-deficient mice were observed in the antigen-induced proliferation of draining lymph node cells obtained from ovalbuminimmunized mice (Fig 6C).

Effect of IL-18 and IFN $\gamma$  on LPS-induced spleen cell proliferation. To investigate the augmented LPS-induced spleen cell proliferation observed in ICE-deficient mice, increasing concentrations of exogenous IL-18 were added to spleen cells of WT and ICE-deficient mice in the presence of LPS, and proliferation was assessed. IL-18 (1 to 100 ng/mL) did not significantly alter LPS-induced spleen cell proliferation in neither WT nor ICE-deficient mice (data not shown). When IL-18 was added alone to spleen cells, in the absence of other stimuli, a significant induction of cell proliferation was observed both in WT and in ICE-deficient mice (Fig 7).

On the other hand, LPS-induced splenocyte proliferation was significantly inhibited both in WT and in ICE-deficient mice when the cells were cultured in the presence of increasing concentrations of IFN $\gamma$ . As shown in Fig 8, at 10 ng/mL of IFN $\gamma$ , the proliferation of ICE-deficient splenocytes was no longer different from that of WT cells.

The effect of neutralization of IL-18 or IFN $\gamma$  on LPS-induced spleen cell proliferation is shown in Table 2. When the proliferation was measured 48 hours after LPS stimulation, neutralization of either IL-18 or IFN $\gamma$  significantly increased spleen cell proliferation. However, when spleen cell prolifera-

tion was measured 72 hours after LPS, only neutralization of IL-18, but not of IFN $\gamma$ , was effective.

Because splenocytes from ICE-deficient mice have decreased IL-1 release after LPS stimulation, we questioned whether the



Fig 6. Increased LPS-induced spleen cell proliferation in ICEdeficient mice. Splenocytes from WT ( $\bullet$ ) or ICE-deficient ( $\bigcirc$ ) mice were incubated for 72 hours with the indicated concentrations of LPS (A) or Con A (B) and proliferation was assessed. Lymph node cells from WT and ICE-deficient mice immunized 14 days before with ovalbumin were incubated for 72 hours with the indicated concentrations of ovalbumin and proliferation was assessed (C). Data are the mean ± SEM of 6 mice per group and are expressed as the percentage of change in MTS absorbance compared with unstimulated cells (100%). \*\*\*P < .001 versus WT by factorial ANOVA.



Fig 7. Effect of IL-18 on spleen cell proliferation. Splenocytes from WT ( $\bullet$ ) or ICE-deficient ( $\bigcirc$ ) mice were incubated with the indicated concentrations of IL-18. Proliferation was assessed after 72 hours of incubation. Data are the mean ± SEM of 3 mice per group and are expressed as the percentage of change in MTS absorbance over unstimulated cells (100%).

lack of IL-1 in ICE-deficient mice could account for the difference in spleen cells proliferation. To assess a role for endogenous IL-1 activity, we blocked IL-1 receptors with IL-1Ra (10  $\mu$ g/mL). The addition of IL-1Ra had no effect on LPS-induced splenocyte proliferation (data not shown). Therefore, a lack of IL-1 in spleen cell cultures in ICE-deficient mice does not account for the increased proliferation of ICE-deficient splenocytes to LPS.

## DISCUSSION

Because of the inability to process pro–IL-18, ICE-deficient mice injected with LPS, with or without preconditioning with *P* acnes, exhibit defective IFN $\gamma$  production.<sup>8,9</sup> In the present report, we investigated whether endogenous IL-18 plays a role in the induction of IFN $\gamma$  after various stimuli. Markedly reduced levels of IFN $\gamma$  were present in splenocytes obtained from ICE-deficient mice after stimulation with two inflammatory stimuli, LPS and zymosan. In contrast, using a direct T-cell mitogen, such as Con A, no differences in IFN $\gamma$  production were observed between WT and ICE-deficient mice. Two explanations are possible for this phenomenon: (1) IL-18, similar to IL-12, is not required for IFN $\gamma$  production after Con A stimulation<sup>18</sup>; and/or (2) ICE is not necessary for the cleavage of



Fig 8. Effect of IFN<sub>Y</sub> on LPS-induced spleen cell proliferation. Splenocytes from WT ( $\bullet$ ) or ICE-deficient ( $\bigcirc$ ) mice were incubated with 20 µg/mL of LPS in the presence of increasing concentrations of IFN<sub>Y</sub>. Proliferation was assessed after 72 hours of incubation. Data are the mean ± SEM of 3 mice per group and are expressed as the percentage of change in MTS absorbance over unstimulated cells (100%). \**P* < .05; \*\**P* < .01 versus WT by factorial ANOVA. <sup>†††</sup> *P* < .001 versus LPS alone by ANOVA for repeated measures.

pro–IL-18 when Con A is the stimulus. We have previously shown that ICE is not always indispensable for release of active IL-1 $\beta$  and that the requirement for ICE in IL-1 $\beta$  processing is stimulus-dependent.<sup>19</sup> It is therefore possible that, similar to pro–IL-1 $\beta$ , ICE-independent pathways might also exist for the cleavage of pro–IL-18. However, the observation that inhibition of endogenous IL-18 reduces IFN $\gamma$  production after LPS or zymosan, but not after Con A, suggests that the first hypothesis is probably correct.

In addition, it should be noted that T lymphocytes as well as B cells, NK cells, and monocytes/macrophages can produce IFN $\gamma$  when an inflammatory stimulus such as LPS is used.<sup>20-22</sup> When LPS is the stimulus, the presence of monocytes/macrophages is also critical, because these cells provide the necessary cytokines (ie, IL-12 and IL-18) that induce IFN $\gamma$  production from lymphocytes and NK cells.<sup>23</sup> By contrast, a mitogen such as Con A can react directly with T cells to induce IFN $\gamma$  production without the need of accessory cells, although cytokines produced by antigen-presenting cells or by bystander lymphocytes (eg, IL-2) play an important regulatory role.<sup>24</sup>

Table 2. Effect of Neutralization of IL-18 or IFN $\gamma$  on LPS-Induced Spleen Cell Proliferation

	LPS Alone	Anti-IL-18 1:400	Anti-IL-18 1:200	Anti–IL-18 1:100	Anti-IFNγ (10 μg/mL)	Anti-IFNγ (30 μg/mL)
48 h	$163.6\pm7.4$	$176.0\pm16.2$	$173.9\pm12.8$	$190.0\pm13.6^{\star}$	179.8 ± 11.6†	$180.3\pm11.3\dagger$
72 h	$164.6\pm3.8$	$185.8 \pm 11.0$	$202.9\pm19.5\dagger$	$207.3\pm19.7\dagger$	$172.4\pm5.8$	$168.2\pm5.8$

Data are expressed as the percentage of change in MTS absorbance compared with unstimulated cells (100%). Splenocytes from WT mice were incubated with LPS (20  $\mu$ g/mL) for 48 or 72 hours in the presence or absence of rabbit antimurine IL-18 antiserum at the indicated dilutions or rat antimouse IFN<sub>Y</sub> at the indicated concentrations. Addition to the cultures of normal rabbit serum at the same concentrations did not significantly alter cell proliferation (data not shown). Data are the mean ± SEM of 3 mice per group.

\**P* < .05.

 $\dagger P < .01$  versus respective LPS alone by ANOVA for repeated measures.

The results obtained in ICE-deficient mice were confirmed by experiments in which endogenous IL-18 was blocked with a neutralizing antiserum. This resulted in a reduction in LPS- and zymosan-induced IFN $\gamma$  levels, but had no significant effect on Con A-induced IFN $\gamma$  production. These results clearly show the critical role played by endogenous IL-18 in the production of IFN $\gamma$  after an inflammatory stimulus and further strengthen the observation that a decreased processing of IL-18 is responsible for the reduced IFN $\gamma$  levels observed in ICE-deficient mice. Furthermore, inhibition of ICE activity reduced LPS-induced IFN $\gamma$  production. However, blockade of IL-1 with IL-1Ra had no inhibitory effect on IFN $\gamma$  levels. These data show that the reduced IFN $\gamma$  levels observed in ICE-deficient mice are not due to the lack of bioactive IL-1.

Expectedly, exogenous IL-18 increased zymosan-induced IFNy production in both WT and ICE-deficient mice. Although the relative increase in IFNy production was higher in ICEdeficient than in WT mice, the absolute amount of IFN $\gamma$  was consistently lower (50%) in cultures from ICE-deficient mice, even when concentrations of exogenous IL-18 up to 100 ng/mL were added. These findings may reflect the lack of an additional factor involved in IFNy production in ICE-deficient mice. Because zymosan-induced IFNy production was not suppressed in splenocytes obtained from IL-1β-deficient mice, it is unlikely that the missing factor is IL-1B. In addition, mRNA expression for both subunits of IL-12, as well as protein levels for the active p70 heterodimer, was not reduced in ICE-deficient mice, thus ruling out the possibility that defective IL-12 production might be responsible for the reduced IFN $\gamma$  levels in ICE-deficient mice. However, homodimers of the p40 subunit of IL-12 can act as antagonists of the p70 heterodimer and hence suppress IFNy induction.<sup>25</sup> Levels of total IL-12 were increased in ICE-deficient splenocytes after stimulation with zymosan, possibly reflecting enhanced production of the p40 homodimer. Therefore, the suppressive activity of p40 homodimers on IFNy production might be enhanced in ICEdeficient mice, thus contributing to the low IFN $\gamma$  levels observed in these mice.

In general, IFN $\gamma$  inhibits proliferation of various cells.<sup>10,11</sup> Accordingly, IFN $\gamma$ -deficient mice have augmented spleen cell proliferation in response to Con A, which is suppressed by exogenous IFN $\gamma$ .<sup>26</sup> Because IFN $\gamma$  production after Con A stimulation is normal in ICE-deficient mice, we did not observe increased splenocyte proliferation with this stimulus. In addition, antigen-induced proliferation of lymph node cells after immunization with ovalbumin was not altered in ICE-deficient mice.

However, consistent with the reduced levels of IFN $\gamma$  observed in ICE-deficient mice after LPS stimulation, spleen cells from ICE-deficient mice underwent increased proliferation when incubated with LPS. Reconstitution with exogenous IFN $\gamma$ inhibited LPS-induced spleen cell proliferation, and the difference between WT and ICE-deficient mice was no longer observed. Accordingly, blockade of endogenous IL-18 or IFN $\gamma$ enhanced LPS-induced spleen cell proliferation. Neutralization of IFN $\gamma$  was effective only when proliferation was measured at 48 hours, but not at 72 hours, after LPS stimulation. These data suggest the role for IL-18 in regulating cell proliferation is only partly dependent on induction of IFN $\gamma$ . When specifically examined, exogenous IL-18 did not influence LPS-induced spleen cell proliferation in WT or in ICE-deficient mice. These results may be possibly confounded by the fact that IL-18, by itself, as previously shown, can provide a proliferative signal.<sup>2,5</sup> The lack of reduction in cell proliferation observed after coincubation with LPS and IL-18 is thus probably a result of two opposite effects of this cytokine: induction of IFN $\gamma$ , which inhibits cell proliferation, and a direct proliferative signal for T cells by IL-18 itself.

Inhibitors of ICE activity are effective in experimental models of inflammatory diseases, such as pancreatitis and collagen-induced arthritis.<sup>27,28</sup> Inhibition of ICE activity is also effective in reducing ischemic and excitotoxic neuronal damage<sup>29</sup> and in delaying lethality in a model of amyotrophic lateral sclerosis.<sup>30</sup> In addition, ICE-deficient mice are protected against LPS-induced toxicity.<sup>31</sup> The reduction in IL-1 $\beta$  and IL-18 release, and consequently of IFN $\gamma$  production, in these models should be considered to account for the ameliorative effects of ICE inhibitors. In view of the possible use of ICE inhibitors as therapeutic agents, it is important to identify those disease conditions in which ICE-cleaved IL-18 plays a critical role.

From the present studies, it appears that T-cell stimuli such as mitogens or specific antigens drive IFN $\gamma$  production without the need for IL-18 processing by ICE. On the other hand, microbial and inflammatory IFN $\gamma$  production is clearly dependent on ICE-mediated cleavage of pro–IL-18. Thus, differential IFN $\gamma$  production reflects the stimulus and inhibiting ICE appears to spare IFN $\gamma$  production induced by T-cell stimuli.

# ACKNOWLEDGMENT

The authors thank Drs Richard A. Flavell and K. Kuida for providing the ICE-deficient mice and Dr H. Zheng for the IL-1 $\beta$ -deficient mice. We also thank J. Keutzer at Genzyme Corp for kindly providing kits for IL-12 measurement.

#### REFERENCES

1. Okamura H, Nagata K, Komatsu T, Tanimoto T, Nukata Y, Tanabe F, Akita K, Torigoe K, Okura T, Fukuda S, Kurimoto M: A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 63:3966, 1995

2. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M: Cloning of a new cytokine that induces IFN- $\gamma$  production by T cells. Nature 378:88, 1995

3. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M: Cloning of the cDNA for human IFN- $\gamma$ -inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156:4274, 1996

4. Rothe H, Jenkins NA, Copeland NG, Kolb H: Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near *Idd2*. J Clin Invest 99:469, 1997

5. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M: Interferon- $\gamma$ -inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon- $\gamma$  production. Eur J Immunol 26:1647, 1996

6. Tsutsui H, Nakanishi K, Matsui K, Higasino K, Okamura H, Miyazawa Y, Kaneda K: IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 157:3967, 1996 7. Bazan JF, Timans JC, Kastelein RA: A newly defined interleukin-1? Nature 379:591, 1996

8. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, Harding MW, Livingston DJ, Su MS-S: Activation of interferon- $\gamma$  inducing factor mediated by interleukin-1 $\beta$  converting enzyme. Science 275:206, 1997

 Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H: Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 386:619, 1997

10. Liu Y, Janeway CA: Interferon gamma plays a critical role in induced cell death of effector T cell: A possible third mechanism of self-tolerance. J Exp Med 172:1735, 1990

11. Gajewski TF, Fitch FW: Anti-proliferative effects of IFN $\gamma$  in immune regulation. I. IFN $\gamma$  inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 140:4245, 1988

12. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS-S, Flavell RA: Altered cytokine export and apoptosis in mice deficient in interleukin-1 $\beta$  converting enzyme. Science 267:2000, 1995

13. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann K, Conn CA, Soszynski D, Grabiec C, Trumbauer ME, Shaw A, Kostura MJ, Stevens K, Rosen H, North RJ, Chen HY, Tocci MJ, Kluger MJ, Van der Ploeg LHT: Resistance to fever induction and impaired acute-phase response in interleukin-1 $\beta$  deficient mice. Immunity 3:9, 1995

14. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W: Current Protocols in Immunology. Vol 1. In Vitro Assays for Mouse Lymphocyte Function. New York, NY, John Wiley & Sons, 1992

15. Goodwin CJ, Holt SJ, Downes S, Marshall NJ: Microculture tetrazolium assays: A comparison between two new tetrazolium salts, XTT and MTS. J Immunol Methods 179:95, 1995

16. Shapiro L, Dinarello CA: Hyperosmotic stress as a stimulant for proinflammatory cytokine production. Exp Cell Res 231, 1997

17. Trinchieri G, Gerosa F: Immunoregulation by interleukin-12. J Leukoc Biol 59:505, 1996

18. Mastroeni P, Harrison JA, Chabalgoity JA, Hormaeche CE: Effect of interleukin 12 neutralization on host resistance and gamma interferon production in mouse typhoid. Infect Immun 64:189, 1996

19. Fantuzzi G, Ku G, Harding MW, Livingston DJ, Kuida K,

Flavell RA, Dinarello CA: Response to local inflammation of IL-1β converting enzyme-deficient mice. J Immunol 158:1818, 1997

20. Heinzel FP, Rerko RM, Ling P, Hakimi J, Schoenhaut DS: Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun 62:4244, 1994

21. Maehara N, Ho M: Cellular origin of interferon induced by bacterial lipopolysaccharide. Infect Immun 15:78, 1977

22. Salkowski CA, Detore GR, Vogel SN: Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 65:3239, 1997

23. Ascher O, Apte RN, Pluznik OH: Generation of lipopolysaccharide-induced interferon in spleen cell cultures. I. Genetic analysis and cellular requirements. Immunogenetics 12:117, 1981

24. Billiau A: Interferon- $\gamma$ : Biology and role in pathogenesis. Adv Immunol 62:61, 1996

25. Heinzel FP, Hujer AM, Ahmed FN, Rerko RM: In vivo production and function of IL-12 p40 homodimers. J Immunol 158:4381, 1997

26. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA: Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739, 1993

27. Norman J, Yang J, Fink G, Carter G, Ku G, Denham W, Livingston D: Severity and mortality of experimental pancreatitis are dependent on interleukin-1 converting enzyme (ICE). J Interferon Cytokine Res 17:113, 1997

28. Ku G, Faust T, Lauffer LL, Livingtson DJ, Harding MW: Interleukin-1 $\beta$  converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8:377, 1996

Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA: Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 94:2007, 1997

30. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J: Inhibition of ICE slows ALS in mice. Nature 388:31, 1997

31. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Jonhston C, McDowell J, Paskind M, Rodman L, Salfeld J, Towne E, Tracey D, Warwell S, Wei F-Y, Wong W, Kamen R, Seshadri T: Mice deficient in IL-1 $\beta$ -converting enzyme are defective in production of mature IL-1 $\beta$ and resistant to endotoxic shock. Cell 80:401, 1995